This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinicaltrial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
” In observational models , patients with legal access to cannabis typically reduce or eliminate their use of opioids. In clinical models, CBD administration has been shown to reduce cravings for tobacco. CBD dosing has also been associated with reduced cravings for methamphetamine in preclinical models.
.” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5
We look forward to his expertise as we expand our mental health analytical platform and enter clinicaltrials. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. ramps up to begin clinicaltrials by adding esteemed medical professional to its medical advisory board.
In nursing school, I wrote my dissertation on the role of the nurse when caring for patients using cannabis therapeutically, knowing that nurses are often the first healthcare professional to whom patients disclose their cannabis use. I remain in awe of these patients to this day.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.
A Windsor, Ontario-based company Audacia Bioscience is especially focussed on three patented technologies that deliver consumer and patient insights to the industry to close the knowledge gaps in the supply chain. Virtual ClinicalTrials transcend geographic, mobility and economic barriers.
The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.
In light of such, and the fact that cancer is a common qualifying condition for cannabis, this research team took to expanding the available basic information on cannabis in the cancer population in order to provide clinicaltrial designers with better information needed for planned studies. Cancer Patients Experience Less Severe Pain.
Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. RoC also works to increase patients’ access to medical cannabis by helping U.S. To date, Veriheal’s global team has helped hundreds of thousands of patients gain access to medical cannabis.
House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinicaltrials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.
In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.
Legal cannabis partnership to help patientaccess. The new distributor in the Australian medicinal cannabis industry – The Entourage Effect – has signed a firstof its kind deal with innovative medical cannabis clinic MiDispensary. As part of the partnership, The Entourage Effect will sell exclusively to patients of MiDispensary.
A medical marijuana patient in Los Angeles with inoperable liver cancer has been removed from Cedars-Sinai Medical Center’s transplant list after testing positive for marijuana. Sixty-three-year-old medical marijuana patient Norman B. The letter also urges Cedars-Sinai to change its transplant eligibility policy. Dr. Steven D.
In the largest clinicaltrial to date, a new study conducted by the UK-based pharmaceutical company Compass Pathways shows that psilocybin or “magic” mushrooms can safely relieve depression. The trial included 233 patients from 10 countries in North America and Europe. Food and Drug Administration.
In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The FDA refers to this program as the expanded access program on their website. A Push by Patients. Patients Are Not In This Alone.
Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. To date, very few human clinicaltrials have been conducted to assess the effectiveness of THC or CBD in treating cancer. The answer: Maybe!
Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinicaltrial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Results highlight the need for expanded patientaccess to CBD products.”.
The results of our successful pivotal Phase 3 clinicaltrial were recently published in Nature Medicine and profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable, and accessible work environment. European Regulatory Lead Executive Summary. Key Responsibilities.
Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. Legislation is pending, HB 350, to expand medical cannabis access. NH resident? GA resident?
A first-of-its-kind Phase 3 clinicaltrial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. Image via. This promising new study is helmed by Rick Doblin, Ph.D.
The study was conducted by COMPASS Pathways , a mental healthcare company that is “dedicated to accelerating patientaccess to evidence-based innovation in mental health.” 233 patients with TRD from 10 countries in North America and Europe received either 1 milligram, 10 milligrams, or 25 milligrams of the COMP360 psilocybin.
This exciting partnership between these innovative startups aims to advance patientaccess to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinicaltrials.”.
There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.
Patients often struggle with symptoms that range from physical discomfort to cognitive impairment. In this article, we explore how medical marijuana for multiple sclerosis symptoms helps patients, with its diverse cannabinoid components, alleviate MS symptoms, and enhance the quality of life for patients.
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinicaltrials’.
. …There’s a lot of activity on the Australian cannabusiness scene, but what is happening at the patient end of things? Below are the numbers of approvals for unapproved products during 2019 via Category B of the Special Access Scheme (SAS). A single patient may have had multiple approvals over the course of 2019.
Dr. Goldstein has treated thousands of patients with medical cannabis. She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. I have used it in some of my patients with autism. But we may be on the cusp of having those trials, which would be very exciting.
The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain. RYAH examined reporting from 17,313 such patients over the course of about 3 ½ years.
CBD passes Stage 3 clinicaltrial for the treatment of epilepsy in children A study published last year in The New England Journal of Medicine saw scientists studying the effects of CBD on epileptic seizures in patients with Dravet syndrome, a severe epileptic disorder leading to frequent and uncontrollable seizures in children.
In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.
Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinicaltrial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Results highlight the need for expanded patientaccess to CBD products.”.
11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patientaccess to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.
reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.
One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. A multitude of recent clinicaltrials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.
This SRA will leverage four other clinicaltrials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The goal at TrPR is to accelerate progress towards impactful and accessible psychedelic treatments.
a necessary question to address as medical marijuana becomes more accessible. ClinicalTrial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. Daily Cannabis Use as a Disqualifier.
Cann Group CEO Peter Crock said of the products: “Satipharm CBD capsules were one of the first medicinal cannabis products available to approved patients in Australia (under the Special Access Scheme) and have been successfully used in a variety of medical conditions since 2017. Shares in Cann Group were up 3.33 per cent to $0.31
Work with squirrel monkeys given access to self-administered cannabinoids has indicated “that cannabinoid reward involves similar brain mechanisms and produces the same kinds of reward-related behavior.” Monkeys are also better suited for assessing the cognitive effects of cannabis and how it can impact human brain development.
After 39 interviews with frontline doctors, researchers, patients, caregivers, practitioners, and expert storytellers, we are taking a summer break as we prepare for season two. The Cannabis Enigma podcast is a co-production of The Cannigma and Americans for Safe Access. The Cannabis Enigma Podcast is wrapping up its first season.
13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinicaltrials seems to support CBD’s positive effects on nociceptive pain (i.e., Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022. Accessed October 17, 2022.
Both Colorado and Oregon allow patients to take psilocybin under the supervision of regulated and licensed “healing centers.” While decriminalization decreases the negative impact of legal issues, it does not provide accessible, safe, and regulated psilocybin for those seeking treatment. Colorado has a wider range of psilocybin use.
A fascinating new clinicaltrial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. All imaging and behavioral data will be accessible to the public after the study is complete. What Is an MRI? Magic Mushrooms: The Ticket to a Stress-Free MRI?
Sleep is not often the focus of clinicaltrials on cannabis; rather it is often a secondary outcome. This direct access to consumers allows MoreBetter to conduct informal studies, collecting data from a set of participants with a selected product over a set amount of time. Has CBN been proven to help with sleep?
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content